Immune Design
Aug 9, 2016

Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Company conference call at 1:30 p.m. PT today

SEATTLE and SOUTH SAN FRANCISCO, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2016.

"The positive data we presented during the second quarter provide a strong rationale for the continued advancement of our two lead programs, CMB305 and G100," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design. "These two programs offer distinct approaches that use the patient's immune system to fight cancer, and which are different from previous efforts in this field."

Recent Highlights

Product Development Progress

Specific Antigen Approach: LV305/CMB305 and ZVex-Neo Programs

CMB305: (1) positive STS signal in early look; and (2) randomized Phase 2 combination study with Genentech's anti-PDL1 antibody, TECENTRIQ® (atezolizumab) ongoing in STS

Intratumoral Immune Activation Approach: Positive Clinical and Translational Data

Expansion of the Team

  Susan L. Kelley M.D. Joins Board of Directors: Addition of Oncology Development Expertise

Financial Results

Second Quarter


Conference Call Information

Immune Design will host a conference call and live audio webcast this afternoon at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss the second quarter 2016 financial results and provide a corporate update.

The live call may be accessed by dialing 844-831-3023 for domestic callers and 920-663-6275 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 59485872.

An archived copy of the webcast will be available on Immune Design's website beginning approximately two hours after the conference call. Immune Design will maintain an archived replay of the webcast on its website for at least 30 days after the conference call.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms, ZVex® and GLAASTM. Both ZVex and GLAAS also have potential applications in infectious disease and allergy as demonstrated by ongoing pharmaceutical collaborations.  Immune Design has offices in Seattle and South San Francisco. For more information, visit

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing and scope of clinical trials for Immune Design's product candidates and the reporting of clinical data regarding Immune Design's product candidates. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrolment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Immune Design Corp. 
Selected Balance Sheet Data  
(In Thousands) 
  June 30,
 December 31, 2015 
Cash and cash equivalents $50,531  $112,921  
Short-term investments  42,058   -  
Total assets  97,791   116,145  
Total current liabilities  10,664   7,111  
Total stockholders' equity  87,064   108,993  

Condensed Consolidated Statements of Operation and Comprehensive Loss Data 
(In Thousands Except Per Share Amounts) 
 Three Months Ended Six Months Ended 
June 30, June 30, 
  2016   2015   2016   2015  
Product sales$733  $19  $740  $108  
Collaborative revenue 400   1,761   2,256   3,610  
Total revenues 1,133   1,780   2,996   3,718  
Operating expenses:        
Cost of product sales 253   44   275   123  
Research and development 11,386   8,483   21,956   15,946  
General and administrative 3,948   3,778   7,862   7,580  
Total operating expenses 15,587   12,305   30,093   23,649  
Loss from operations (14,454)  (10,525)  (27,097)  (19,931) 
Interest and other income 107   8   456   8  
Net loss$(14,347) $(10,517) $(26,641) $(19,923) 
Other comprehensive income:        
Unrealized gain on investments 10   -   30   -  
Comprehensive loss:$(14,337) $(10,517) $(26,611) $(19,923) 
Basic and diluted net loss per share$(0.71) $(0.54) $(1.32) $(1.10) 
Weighted-average shares used to compute basic and diluted net loss per share 20,155,410   19,356,404   20,154,306   18,174,611  
Media Contact
Julie Rathbun
Rathbun Communications                   

Investor Contact
Shari Annes
Annes Associates